TMS Co., Ltd. (4891) AI Stock Analysis

1 Followers

TMS Co., Ltd.

(TSE/TYO:4891)

Select Model

Rating:55Neutral

Price Target:JPY 114.00▼(-17.39% Downside)

Action:reiterated

Date:09/20/26

Financial performance is the dominant factor with volatility, losses, and cash burn in this development-stage biotech, though a debt-free balance sheet provides some stability. Bullish technical momentum offers support while negative P/E weighs on valuation.

Positive Factors

Low Financial LeverageA debt-free balance sheet reduces mandatory interest and repayment demands, giving TMS greater resilience during operating losses. This conservative financing profile preserves financial flexibility and may allow management to direct available resources toward research, development, or recovery initiatives.

Negative Factors

Persistent Operating LossesSeveral consecutive years of deep operating and net losses indicate that current activities are not producing dependable earnings. This weak profitability can consume capital, restrict reinvestment, and make a sustained recovery dependent on improved commercialization or additional funding.

TMS Co., Ltd. (4891) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 6.35B
Dividend Yield: ―
Average Volume (3M): 443.83K
Price to Earnings (P/E): -6.3
Beta (1Y): 0.34
Revenue Growth: ―
EPS Growth: ―
Country: Japan
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

TMS Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The co...

TMS Co., Ltd. Financial Statement Overview

Summary

High volatility with persistent net losses and cash burn typical of early-stage biotech, offset by debt-free balance sheet and positive equity.

Income Statement

15Very Negative

Balance Sheet

60Neutral

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Feb 2025	Feb 2024	Feb 2023	Feb 2022
Income Statement
Total Revenue	0	0	0	0	0	1.95B
Gross Profit	-501.00K	-314.40K	-3.71M	-6.95M	-6.60M	1.74B
EBITDA	-1.03B	-836.05M	-655.89M	-937.00M	-513.55M	1.14B
Net Income	-699.20M	-859.27M	-660.55M	-960.04M	-860.92M	1.08B
Balance Sheet
Total Assets	3.21B	2.87B	3.03B	3.55B	3.79B	2.74B
Cash, Cash Equivalents and Short-Term Investments	3.18B	2.78B	2.92B	3.45B	3.58B	2.60B
Total Debt	0	0	0	0	0	0
Total Liabilities	122.98M	95.00M	216.78M	97.69M	76.16M	286.78M
Stockholders Equity	3.09B	2.77B	2.82B	3.46B	3.71B	2.45B
Cash Flow
Free Cash Flow	0	-782.43M	-524.60M	-826.17M	-702.14M	1.25B
Operating Cash Flow	0	-779.89M	-493.76M	-822.81M	-688.42M	1.26B
Investing Cash Flow	0	-2.54M	-30.84M	-3.36M	-13.72M	-16.96M
Financing Cash Flow	0	640.52M	919.00K	688.13M	1.69B	246.48M

TMS Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price138.00

Price Trends

50DMA125.22Positive

100DMA114.42Positive

200DMA128.00Positive

Market Momentum

MACD3.31Positive

RSI57.05Neutral

STOCH35.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4891, the sentiment is Positive. The current price of 138.00 is above the 20-day moving average (MA) of 131.55, above the 50-day MA of 125.22, and above the 200-day MA of 128.00, indicating a bullish trend. The MACD of 3.31 indicates Positive momentum. The RSI at 57.05 is Neutral, neither overbought nor oversold. The STOCH value of 35.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4891.

TMS Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4891 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:7096	56Neutral	JPY 6.59B	45.92	―	―	4.85%	-40.57%
JP:4891	55Neutral	JPY 6.49B	-6.27	―	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4593	49Neutral	JPY 32.26B	48.59	―	―	-47.32%	―
JP:4978	43Neutral	JPY 11.97B	-24.40	―	―	-18.71%	-246.54%
JP:4599	38Underperform	JPY 7.46B	-4.04	―	―	―	4.85%
JP:7776	26Underperform	JPY 6.90B	-5.90	―	―	-56.16%	3.12%

* Healthcare Sector Average

Performance Comparison

JP:4891 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4891	TMS Co., Ltd.	138.00	-8.00	-5.48%
JP:4593	Healios KK	241.00	-220.00	-47.72%
JP:4599	StemRIM Inc.	119.00	-168.00	-58.54%
JP:4978	ReproCELL Inc.	115.00	-53.00	-31.55%
JP:7096	StemCell Institute	668.00	-141.00	-17.43%
JP:7776	CellSeed Inc.	171.00	-261.00	-60.42%

TMS Co., Ltd. Corporate Events

TMS Co. Cleared to Start Phase IIa Trial of TMS-008 for Post-Surgical Acute Kidney Injury

Oct 15, 2026

TMS Co., Ltd. reported that Japan’s Pharmaceuticals and Medical Devices Agency has completed the mandated 14-day review of its Clinical Trial Plan Notification for a Phase IIa study of TMS-008. With this regulatory step finalized, the company can now...

TMS Co. Files Phase IIa Trial Plan for Acute Kidney Injury Drug TMS-008

Sep 30, 2026

TMS Co., Ltd., a clinical-stage biopharmaceutical company specializing in SMTP-derived small molecules for severe conditions such as acute ischemic stroke, acute kidney injury and spinal cord injury, is advancing a pipeline aimed at areas of high unm...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 20, 2026

TMS Co., Ltd. AI Stock Analysis